Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage patients with a complete response (CR)or partial response (PR) using the revised response criteria for malignant lymphoma (Cheson et al 2007)
From randomization until disease progression (expected duration of treatment approximately 6 months)
No
Jeffrey Skolnik, MD
Study Director
Sponsor GmbH
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D4302C00001
NCT01499303
December 2011
December 2013
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Ames, Iowa |
Research Site | Baltimore, Maryland |
Research Site | Beverly, Massachusetts |
Research Site | Alexandria, Minnesota |
Research Site | Branson, Missouri |
Research Site | Belleville, New Jersey |
Research Site | Albany, New York |
Research Site | Akron, Ohio |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |